Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel-Reference-Cited by-同舟云学术

Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel

Published:2017-02-07 Issue:12 Volume:123 Page:2303-2311
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Armstrong Andrew J.¹,Saad Fred²,Phung De³,Dmuchowski Carl⁴,Shore Neal D.⁵,Fizazi Karim⁶,Hirmand Mohammad⁷,Forer David⁷,Scher Howard I.⁸,Bono Johann De⁹

Affiliation:

1. Duke Cancer Institute; Durham North Carolina

2. Centre Hospitalier de l'Université de Montréal and CRCHUM; Montreal Quebec Canada

3. Astellas Pharma, Inc.; Leiden Netherlands

4. Astellas Pharma, Inc.; Northbrook Illinois

5. Carolina Urologic Research Center; Myrtle Beach South Carolina

6. Institut Gustave Roussy; University of Paris Sud; Paris France

7. Medivation, Inc.; San Francisco California

8. Sidney Kimmel Center for Prostate and Urologic Cancers and Memorial Sloan-Kettering Cancer Center; New York New York

9. Institute of Cancer Research; London UK

Funder

Astellas Pharma, Inc.

Medivation, Inc.

Pfizer, Inc.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference28 articles.

1. International Agency for Research on Cancer GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx 2016

2. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med.,2014

3. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;Bono;Lancet.,2010

4. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study;Fizazi;Lancet Oncol.,2012

5. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases;Nilsson;Clin Genitourin Cancer.,2013

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial;European Urology;2024-09

2. Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study;European Urology Oncology;2024-04

3. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer;New England Journal of Medicine;2023-10-19

4. Canonical and truncated transglutaminase-2 regulate mucin-1 expression and androgen independency in prostate cancer cell lines;Cell Death & Disease;2023-05-09

5. Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial;Journal of Urology;2023-03